In 2025, Turbine took the first steps in opening its powerful cell simulation platform to the wider drug development ...

As clinical trial complexities grow, ICH E6 (R3) updates emphasize smarter monitoring, greater participant focus, and a ...

A federal district court in Delaware ruled that Viatris’ product, currently awaiting approval from the US Food and Drug Administration (FDA), does not infringe on Novo Nordisk’s patent for the ...

The EC has approved Janssen-Cilag International’s new indication for Darzalex Faspro (daratumumab) to treat adults with SMM.

Kling Bio has entered a partnership and licence option agreement with Sanofi to discover neutralising antibodies and epitopes.

Positive topline results of Apnimed's LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.

AstraZeneca has announced $50bn investment plans in the US by 2030 for drug manufacturing and research and development (R&D).

The UK is the first country to introduce a dedicated law to decentralise manufacturing of personalised medicines at the point of care.

Biogen has announced plans to invest an additional $2bn in Research Triangle Park (RTP) in the US state of North Carolina. The latest manufacturing investment will support the ongoing development of ...

Fangzhou has signed a MoU with Novo Nordisk to collaborate on the management of serious chronic diseases, including obesity and diabetes.

Sanofi has completed its acquisition of Blueprint, enhancing its portfolio with a commercialised therapy and expertise focused on SM.

Pharmaceutical companies and manufacturers, including MilliporeSigma (Burlington, US), Simtra BioPharma Solutions (Parsippany, US), Carbogen AMCIS (Bubendorf, Switzerland), and BioNTech (Mainz, ...